Personalized mRNA vaccine cuts melanoma return risk in phase 3 trial
โฎ BeforeMelanoma can return after treatment, and patients face a risk of recurrence.
โ
NowA phase 3 trial reports a personalized mRNA vaccine cut that risk by 42 percent.
In short
- A phase 3 clinical trial tested a personalized mRNA vaccine from Merck and Moderna.
- The source reports the vaccine cut the risk of melanoma returning by 42 percent.
- The results come from a trial, so the treatment's wider use is still to be confirmed.
Why it's good news
Melanoma can return after surgery, and that fear shapes years of follow-up for patients. This phase 3 trial tested a vaccine tailored to each patient's tumour. The source reports a 42 percent cut in the risk of return.
Advertisement
From Inc.
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
Ask this story
๐ The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
- 24 Oct 2026 Personalized mRNA Vaccine Cuts Melanoma Recurrence by Over 40 Percent The same personalized mRNA melanoma vaccine's Phase 3 trial result is now reported as cutting recurrence risk by over 40 percent.
- 25 Oct 2026 A cancer vaccine shows its first success and researchers push to widen it The personalized mRNA cancer vaccine's melanoma trial success is now seen as a first clear win, and researchers aim to extend it to more tumor types.
- 26 Oct 2026 Personalized mRNA vaccine cuts melanoma return risk in phase 3 trial The same personalized Moderna and Merck melanoma vaccine has now been reported in a phase 3 trial, confirming its effect on recurrence risk.
More like this
Advertisement